Protocol Ledger

NCT04066023 · Phase II/III · COMPLETED

Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches

Interventional Phase II/III clinical trial protocol NCT04066023 sponsored by Zosano Pharma in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-03 Enrollment: 42 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04066023
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)42 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04066023
Protocol FieldVerified Registry Value
NCT IdentifierNCT04066023
Consolidated Lead SponsorZosano Pharma
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment42 participants (ACTUAL)
Registered Start Date2019-10-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI